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and OATP1B3 and are primarily expressed on the basolateral membrane of hepatocytes, whereas others, like OATP2B1, have a much broader expression pattern (Hagenbuch and Meier, 2004) . OATP2B1 is expressed in liver, placenta, small intestine, kidney, brain, skin, heart, platelets, and skeletal muscle (Hagenbuch and Meier, 2004; Knauer et al., 2010; Kullak-Ublick et al., 2001; Niessen et al., 2009; Tamai et al., 2000) . A wide variety of drugs are transport substrates of OATP2B1 including benzylpenicillin (Tamai et al., 2000) , bosentan (Treiber et al., 2007) , ezetimibe-glucuronide (Oswald et al., 2008) , fexofenadine (Nozawa et al., 2004a) , glibenclamide (Satoh et al., 2005) , troglitazone (Nozawa et al., 2004b) , atorvastatin (Grube et al., 2006) , fluvastatin (Kopplow et al., 2005) , pitavastatin (Shirasaka et al., 2011) , pravastatin (Shirasaka et al., 2010) , and rosuvastatin (Ho et al., 2006) as well as steroid sulfate conjugates like estrone sulfate (E1S) (Tamai et al., 2001) . OATP2B1 has been implicated in the pH dependent absorption of multiple drugs across the human intestine epithelial cells (Kobayashi et al., 2003; Nozawa et al., 2004a) . OATP2B1, like OATP1B1 and OATP1B3, is thought to mediate the sodium independent uptake of amphiphilic organic anions into the liver (Aoki et al., 2009) . Given expression in placenta and mammary gland, OATP2B1 has been connected to the uptake and supply of precursor molecules for steroid synthesis M O L # 8 3 6 1 8 r e v 2 5 (Ugele et al., 2003) . Previously, we have described a potential role for OATP2B1 in the skeletal muscle statin uptake and sensitization to toxicity .
Originally cloned from human brain, OATP2B1 is predicted to be a 709 amino acid protein (Kullak-Ublick et al., 2001; Tamai et al., 2000) . Gene regulation analysis using promoter reporters in intestinal and liver cells revealed that the constitutive expression of the originally cloned OATP2B1 protein variant was regulated by the Sp1 transcription factor (Maeda et al., 2006) . Recently, Pomari and colleagues have shown that differential promoter usage in tissues results in the expression of several OATP2B1 transcription start site (TSS) variants ( Fig. 1 ) (Pomari et al., 2009 ). These OATP2B1 variants utilize 5 distinct first exons and associated promoters but share common subsequent exons (exons 2 to 14). One TSS variant represents the original full length (709 amino acids) protein with translation start site within this first exon (termed exon 1b). The other variants arising from transcription initiation at exons 1a, 1c, 1d and 1e are expected to produce a shorter protein (687 amino acids) than the 1b variant, as translation is predicted to start in exon 2. Hence, the short OATP2B1 protein variants lack 22 amino acids from the N-terminus in comparison to the original full length form. To date, there is an absence of information regarding the relative expression of the OATP2B1 transporter variants in key tissues responsible for drug absorption and elimination. Moreover, the transport competency of the short OATP2B1 protein has not previously been demonstrated. In this report, we find that the short OATP2B1 transporter variant is the predominant form expressed in human liver while the major form in small intestine is the full length version. We also demonstrate liver enrichment of the short OATP2B1 variant was partly due to transcriptional regulation by hepatocyte nuclear factor 4α (HNF4α). were cultured in DMEM supplemented with 10% FBS, 50 U/mL penicillin, 50 μ g/mL streptomycin and 2 mM L-glutamine (Invitrogen, Carlsbad, CA). Cells were maintained at 37°C in a humidified atmosphere of 5% CO 2 and 95% air. The cells were plated onto 12-well plates for transport studies and 24-well plates for dual luciferase reporter assays at a density of ~1 × 10 6 cells/mL.
liver cDNA library using oligonucleotide primers (Table 1) and ligated into pEF6/V5-His-TOPO vector (Invitrogen).
Adenoviral
Vectors. An adenoviral vector containing OATP2B1-Short was generated using the ViraPower Adenoviral Expression System (Invitrogen) as previously described for OATP2B1-FL RNA from a cohort of 23 healthy human livers and 17 intestinal samples were obtained from healthy individuals undergoing diagnostic esophagogastroduodenoscopy was described elsewhere (Ho et al., 2006; Urquhart et al., 2010 Membranes were probed with custom-made rabbit polyclonal OATP2B1 antibody based on a C-terminus epitope (CSPAVEQQLLVSGPGKKPEDSRV) (Invitrogen). Anti-rabbit horseradish peroxidase-labeled antibody (Bio-Rad, Hercules, CA) was used as the secondary. The immobilized secondary antibody was detected using the ECL Plus Western Blotting Detection System (GE Healthcare) and KODAK ImageStation 4000 MM (Mandel). HeLa cells were transduced with adenovirus encoding LacZ (control), OATP2B1-FL or OATP2B1-Short on culture slides and were stained as previously described Cells were transfected with 1 µg of transporter cDNA or parental plasmid lacking insert as control using Lipofectin (Invitrogen) and incubated at 37°C for 16h. To examine pH dependent transport of OATP2B1, HeLa cells were transduced with the adenoviruses containing the full length or short OATP2B1 variant transporter coding region in DMEM medium at a multiplicity of infection (MOI) of 100 and incubated at 37°C for 48h.
Transport was evaluated in Opti-MEM I using labeled substrate as previously reported (Cvetkovic et al., 1999) . Drug accumulation was determined after 5 min for rosuvastatin, 10 min for estrone 3-sulfate, and 10 min for taurocholate by washing cells three times with ice-cold PBS followed by lysis with 1% sodium dodecylsulfate. Retained cellular radioactivity was quantified by liquid scintillation spectrometry. Concentrationdependent transport by OATP2B1 variants was performed at various substrate levels (rosuvastatin 0.1 to 20 μM; estrone 3-sulfate 0.1 to 100 μM). were incubated for 24h at 37°C. Cells were then rinsed with PBS and harvested using passive lysis buffer (Promega). Luciferase activity was measured in cell extracts using Dual-Luciferase reporter assay (Promega) and detected using a Flouroskan Ascent FL luminometer (Thermo Scientific, Hudson, NH). Relative luciferase activity is reported as the ratio of firefly/Renilla luciferase activities. Nuclear receptor expression vectors were prepared as previously described (Tirona et al., 2003b) and in certain instances, 250 or 500 ng/well of each nuclear receptor expression plasmid or blank vector control plasmid were used for reporter assays. (Table 2 for primer sequences). Western Blot of total cell lysates was performed using anti-HNF4α C-19 (sc-6556; Santa Cruz Biotechnology)
(1:1000) and anti-actin C-11 (sc-1615; Santa Cruz Biotechnology) (1:200).
Statistical Analysis. Statistical differences between group parameters was determined by unpaired T-test, 1-way ANOVA, or 2-way ANOVA, using Bonferroni's multiple This article has not been copyedited and formatted. The final version may differ from this version. Results.
Tissue Expression of OATP2B1 TSS variants. We performed variant-specific quantitative RT-PCR to determine the absolute expression of the OATP2B1 variants in tissues important in drug disposition, namely the duodenum and liver. While transcripts for the OATP2B1 1b, 1d and 1e variants were readily observed; we were not able to detect OATP2B1 1a and 1c transcripts in these tissues (not shown). In duodenum, the OATP2B1 variant 1b, encoding the full length protein variant was the most abundant transcript ( Fig. 2 ). On average, OATP2B1 1d and 1e transcripts were 10-fold lower than 1b transcripts in the intestine. In liver, OATP2B1 1e transcript (short variant) was the predominant form followed by 1b and 1d transcripts. It is notable that for each transcript, the absolute expressions of OATP2B1 1b and 1d were similar when comparing duodenum versus liver levels. The clear exception was for the OATP2B1 1e transcript, whose expression was 100-fold greater in liver than in duodenum. We confirmed that the OATP2B1 1e transcript detected by qPCR arose from an mRNA encoding the short protein variant by long range PCR using liver cDNA template, cloning of the amplicon and sequencing.
Variant-specific quantitative RT-PCR of OATP2B1 variants was also performed in samples of kidney, brain, placenta, and skeletal muscle. Like liver and intestine, transcripts for OATP2B1 1b, 1d, and 1e were observed, but OATP2B1 1a and 1c transcripts were not detected in these tissues (Table 3) . Similar to duodenum, the OATP2B1 1b variant was the most abundant transcript found in kidney, brain, placenta and skeletal muscle. Again we noted, the absolute expressions of OATP2B1 1b transcripts (full length form) in kidney, placenta and skeletal muscle were similar when Transport Function of OATP2B1-Short. Many groups have studied the transport function of OATP2B1-FL but to our knowledge the transport function of the short variant has not been previously assessed. Here, we examined the transport function of the OATP2B1-Short variant in comparison to OATP2B1-FL using three substrates: estrone 3-sulfate, rosuvastatin, and taurocholate. Both OATP2B1-FL and OATP2B1-Short show time-and concentration-dependent uptake kinetics for estrone 3-sulfate and rosuvastatin ( Fig. 3C-F) . The apparent affinities (K m ) for both substrates were not significantly different between OATP2B1-FL and OATP2B1-Short (Table 4) . The maximal velocity (V max ) of the OATP2B1-Short was slightly higher for both rosuvastatin and estrone 3-sulfate; however, the differences did not reach statistical significance (Table 4) . Transport clearance (CL) of the OATP2B1-Short was also slightly higher for both rosuvastatin and estrone 3-sulfate but it also did not reach statistical significance. Heterologous expression
of OATP2B1-FL and OATP2B1-Short in HeLa cells, using recombinant adenoviruses and protein detection with an OATP2B1 antibody directed towards a common Cterminus epitope, showed that both variants products are expressed at comparable levels as determined by densitometric analysis of the Western Blot (actin normalized relative expression: LacZ (100%), OATP2B1-FL (396%) and OATP2B1-Short (432%)). Both OATP2B1 variants traffic to the cell surface as revealed by indirect immunofluorescence (Fig 3A and B) . Interestingly, basal OATP2B1 expression was detected by immunoblot ( Fig. 3A) and immunofluorescence under higher gain/exposure setting (not shown) while quantitative PCR measured very low levels of the full length OATP2B1 transcript (Table   3 ) in HeLa cells which may account for some uptake of estrone 3-sulfate and rosuvastatin in vector control transfected cells ( Fig. 3C and D) . These findings indicate that the SLCO2B1 1e promoter transcript produces a short transporter variant with similar transport activity as the previously characterized full length OATP2B1 protein.
We further examined the pH dependent transport of the OATP2B1-Short variant since previous studies have demonstrated OATP2B1-FL transports certain substrates, including estrone 3-sulfate and taurocholate, in a pH dependent manner (Kobayashi et al., 2003; Nozawa et al., 2004a) . For both the full length and the short OATP2B1 variants, we observed that rosuvastatin transport was stimulated with decreasing pH (Fig 4A) .
Rosuvastatin transport by OATP2B1-Short is significantly greater than OATP2B1-FL at low pH (5.5 and 6.0) but not at higher pH (6.5 and 7.2) (Fig. 4A) . In contrast, estrone 3-sulfate transport activities for both OATP2B1-FL and OATP2B1-Short do not appear to be pH-dependent (Fig. 4B ). Despite that a previous report had demonstrated stimulation of taurocholate uptake by OATP2B1 by low pH (Nozawa et al., 2004a) , we did not
observe OATP2B1-dependent taurocholate transport under any experimental condition (Fig. 4C) . These results suggest that amino acids in the predicted intracellular N-terminus of OATP2B1 modulates substrate-specific, pH-dependent membrane transport.
Transactivator Screen of the SLCO2B1 1e Promoter. The full length form of OATP2B1 appears to be ubiquitously expressed in many tissues and the constitutive expression of OATP2B1-FL is under regulatory control by the Sp1 transcription factor (Maeda et al., 2006) . However, regulatory control mechanisms of the other OATP2B1
TSS variants have not been previously assessed. We have focused on the OATP2B1 1e TSS variant because it shows liver specific expression unlike the OATP2B1 1b variant found ubiquitously (Pomari et al., 2009) (Fig. 2 and Table 3 ). The SLCO2B1 1e promoter was cloned from genomic DNA (-2250 to +78) and ligated into pGL3-basic luciferase reporter. The +1 position was considered to be the transcription start site of exon 1e
described by Pomari and colleagues (GeneBank no. FM209054) (Pomari et al., 2009 ).
We screened the ability of a variety of nuclear receptors (HNF4α, constitutive androstane receptor, liver X receptor, pregnane X receptor, small heterodimer partner 1, peroxisome proliferator activated receptors α and γ , liver receptor homolog 1 and vitamin D receptor)
to activate the SLCO2B1 1e promoter using co-transfection and luciferase reporter assays in HeLa cells (Fig. 5A ). Of the nuclear receptors analyzed, we found that HNF4α strongly transactivated the SLCO2B1 1e (-2250/+78) promoter. Interestingly, we found that HNF4α did not transactivate the SLCO2B1 1b promoter (Fig. 5B ).
M
Deletion-Mutation Analysis of SLCO2B1 1e Promoter Activity. Reporter assays were performed in liver (HepG2 and Huh-7), colon (Caco-2) and cervical carcinoma (HeLa) cell lines to evaluate the roles of cellular milieu and cis-acting factors to SLCO2B1 1e promoter activity. For this purpose, SLCO2B1 1e promoter constructs were created by sequentially deleting the 5' upstream segments (-2250 to +78, -1000 to +78, -500 to +78
and -200 to +78). We observed reporter activity in three cell lines (HepG2, Huh-7 and Caco-2) for all SLCO2B1 1e deletion constructs (Fig. 6A) . In comparison, SLCO2B1 1b reporter activity was significantly lower than of SLCO2B1 1e. The pattern of reporter activity was similar for all cell lines except for HeLa cells, which displayed no significant activity for all reporter constructs. Reporter activity decreased upon the deletion of -2250
to -1000 region, suggesting the presence of positive regulatory sequences. While deletion of the -1000 to -500 revealed a large increase in reporter activity in three cell lines (HepG2, Huh-7 and Caco-2) suggesting that the deleted segment contains negative regulatory sequences. Even the shortest construct (-200/+78) retained reporter activity in HepG2, Huh-7 and Caco-2 suggesting the presence of an important positive regulatory sequence in this region.
Given that OATP2B1 le transcripts are prominently expressed in liver and that SLCO2B1 1e luciferase reporter activities were higher in hepatic and intestinal cell lines in comparison to cervical carcinoma cells, we suspected a role for liver enriched transcription factors such as HNF4α in regulating gene expression. Hence, we performed in silico analysis of transcription factor binding sites within the 2.5 Kb fragment of the SLCO2B1 1e gene promoter using the NUBIscan algorithm (Podvinec et al., 2002) .
site for HNF4α (Bolotin et al., 2010) , were predicted which we have termed DR1-1 (AGGGCAaAGTCCA) located at position -17 to -4, a DR1-2 (AGGCCTcAGACCT) located at -954 to -941 and DR1-3 (AGAGCAaGGGCCA) located at -2149 to -2136. On the basis that the -200/+78 construct had retained significant activity in liver and intestinal cells, we hypothesized that the DR1-1 site would represent a functional HNF4α binding site. Guided by the position weight matrix for HNF4α-binding sequence motifs (Bolotin et al., 2010) , the DR1-1 site was mutated at three key base pairs (Fig. 6B) .
Furthermore, we deleted three base pairs in DR1-1 to disrupt the HNF4α motif spacing (Fig. 6B ). Reporter assays were performed in HeLa cells transfected with HNF4α and the DR1-1 mutation constructs (Fig. 6C) . It is notable that in contrast to HepG2, Huh-7 and
Caco-2 cells, HeLa cells do not express native HNF4α (Fig. 6D) . Disruption of the DR1-1 response element by mutation or deletion significantly decreased the transcriptional activation of the SLCO2B1 1e promoter by HNF4α, suggesting that the DR1-1 site is a functional HNF4α binding site (Fig. 6C ). These studies demonstrate that the SLCO2B1 1e
promoter contains a functional HNF4α-binding sequence near the 1e transcription start site.
Analysis of SLCO2B1 1e Gene Expression and Promoter Activity after HNF4α
Knockdown with siRNA. We found that Huh-7 cells extensively express both OATP2B1 1b and 1e transcripts ( knockdown on SLCO2B1 1e promoter activity (Fig. 7B) . siRNA knockdown of HNF4α significantly decreased the transcriptional activation of SLCO2B1 1e promoter constructs of various lengths, including the (-200/+78) reporter containing the DR1-1 binding site.
Collectively, these results suggest that HNF4α expression affects OATP2B1 1e variant levels through a transcriptional mechanism.
HNF4α Binding to SLCO2B1 1e Promoter. To confirm that HNF4α binds to the DR1-1 response element, chromatin immunoprecipitation (ChIP) was performed with a HNF4α antibody in HeLa, HepG2, Huh-7 and Caco-2 cells. HNF4α-bound DNA was used as template for real-time PCR using primers designed to cover sequences along the SLCO2B1 1e promoter covering 2.2 Kb upstream and the three predicted DR1 response elements (Fig. 8A) . The analysis revealed significant binding of HNF4α to the proximal region of the SLCO2B1 1e promoter near the DR1-1 (-4 bp) response element in HepG2, Huh-7 and Caco-2 cells but not HeLa cells (Fig. 8B) Discussion.
In the present study, we characterized the transport function and transcriptional regulation of OATP2B1 1e variant. The SLCO2B1 1e variant encoding OATP2B1-Short was cloned from a human liver cDNA library. Heterologous expression of OATP2B1-Short (1e) in HeLa cells resulted in cell surface expression and functional transport activity. We found no pronounced differences in transport activity between the OATP2B1-FL and OATP2B1-Short protein for two typical OATP substrates:
rosuvastatin and estrone 3-sulfate. However, we did see a significant increase in rosuvastatin uptake by OATP2B1-Short, but not for OATP2B1-FL at low pH. Reporter assays, siRNA knockdown and chromatin immunoprecipitation revealed a functional HNF4α binding motif in the proximal region of the SLCO2B1 1e promoter.
The expression of the alternative OATP2B1 variants in intestine and kidney were reported previously (Pomari et al., 2009) . We confirm that the OATP2B1 exon 1b transcription variant has broad expression pattern consistent with previous reports and regulation by a constitutive nuclear receptor Sp1 (Maeda et al., 2006; Pomari et al., 2009 ). Quantitative PCR revealed that expression of the OATP2B1 1b full length variant was highest in the brain, the tissue of first cloning (Tamai et al., 2000) . We confirm the liver enriched expression of the OATP2B1 exon 1e variants using absolute quantitative PCR, as was previously suggested using semi-quantitative PCR (Pomari et al., 2009 ).
Interestingly we report 100-fold variation in the hepatic mRNA expression of the OATP2B1 1e variant between individuals.
We demonstrate that the SLCO2B1 1e variant encodes a shortened protein capable of trafficking to the cell surface and has functional transport activity. While there was a
non-significant trend towards higher transport efficiency for OATP2B1-Short in comparison to OATP2B1-FL during studies with concentration-dependent uptake, clear differences were observed in the transport efficiencies among the variants at low pH.
Other studies have also documented the pH dependent transport of rosuvastatin, fluvastatin, pravastatin, atorvastatin, cerivastatin, and pitavastatin by OATP2B1 (Kobayashi et al., 2003; Varma et al., 2011) . Previous studies have demonstrated pH dependent transport of estrone 3-sulfate by OATP2B1; however, we did not detect a significant difference in the pH dependent transport of estrone 3-sulfate (Kis et al., 2010; Kobayashi et al., 2003; Nozawa et al., 2004a; Sai et al., 2006) . It has been recently shown that the transport of estrone 3-sulfate by OATP2B1 is mediated by high-and low-affinity components, with only the low-affinity component being pH sensitive (Shirasaka et al., 2012) . The concentration of estrone 3-sulfate used in our study (100 nM) was low, likely explaining why we did not see pH dependent transport by the low-affinity transport component (K m 29.9 μ M) (Shirasaka et al., 2012) . Previous studies have demonstrated transport of the bile acid taurocholate by OATP2B1 at low pH (<pH 6.5) but not at physiological pH of (7.4 or 7.5) (Kullak-Ublick et al., 2001; Nozawa et al., 2004a) , however, we did not detect transporter-specific taurocholate uptake at any pH. It has been suggested that an inward proton gradient acts as the driving force for the OATP2B1 mediated intestinal absorption and cellular uptake of substrates (Nozawa et al., 2004a; Sai et al., 2006; Varma et al., 2011) . The pH sensitivity of OATP2B1 has been linked to a conserved histidine in transmembrane domain three (Leuthold et al., 2009) . Here, we propose a role for the amino acids in the predicted intracellular N-terminus in modulating substrate-specific, pH-dependent membrane transport of OATP2B1.
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In this study, the liver specific nuclear receptor, HNF4α, was found to stimulate transcription of the SLCO2B1 exon 1e promoter. Moreover, a functional HNF4α binding motif was found in the proximal region of the SLCO2B1 1e gene promoter very close to the transcription start site. Indeed, others have recently identified this HNF4α binding motif in the SLCO2B1 exon 1e promoter using the ChIP-Seq method (Fang et al., 2012) .
HNF4α is expressed highly in metabolic tissues like the liver, kidney and intestine (Bookout et al., 2006) . HNF4α has been shown to regulate key drug metabolism genes including Cytochromes P450 ( 
In this report, we assessed the transport function and regulation of the liverenriched OATP2B1 1e transcription start site variant. The encoded OATP2B1-Short protein is a functional membrane transporter for estrone 3-sulfate and rosuvastatin.
Analysis of the SLCO2B1 1e TSS variant promoter revealed a DR1 binding motif capable of binding HNF4α to control the liver specific expression of the short OATP2B1 1e
variant. These findings indicate that differential regulation of OATP2B1 splice variant expression in tissues could contribute to variation in drug response.
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